Download
1-s2.0-S2352771420300380-main.pdf 400,75KB
WeightNameValue
1000 Titel
  • Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
1000 Autor/in
  1. Amirian, E. Susan |
  2. Levy, Julie K. |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-06-01
1000 Erschienen in
1000 Quellenangabe
  • 9:100128
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1016/j.onehlt.2020.100128 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118644/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734™) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence about the antiviral effects of remdesivir against coronaviruses is primarily based on in vitro and in vivo studies (including some on a chemically related compound, GS-441524™), which have demonstrated largely favorable findings. As the pandemic progresses, information from human compassionate use cases will continue to accumulate before the clinical trials are concluded. It is imperative for public health practitioners and the One Health community to stay up to date on the most promising potential therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize the knowledge to date about remdesivir as a therapeutic option for coronaviruses, with a special focus on information relevant to the One Health community.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Compassionate use
lokal Remdesivir
lokal GS-5734
lokal SARS-CoV-2
lokal Coronavirus
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/QW1pcmlhbiwgRS4gU3VzYW4=|https://frl.publisso.de/adhoc/uri/TGV2eSwgSnVsaWUgSy4=
1000 Label
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6421400.rdf
1000 Erstellt am 2020-06-18T11:36:57.855+0200
1000 Erstellt von 122
1000 beschreibt frl:6421400
1000 Bearbeitet von 122
1000 Zuletzt bearbeitet Thu Jun 18 11:38:26 CEST 2020
1000 Objekt bearb. Thu Jun 18 11:38:05 CEST 2020
1000 Vgl. frl:6421400
1000 Oai Id
  1. oai:frl.publisso.de:frl:6421400 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source